Market Intel: The Changing Dynamics Of Newer-Generation Drug-Eluting Stents
The global vascular stents market is expected to reach $8.8bn by 2021, driven primarily by the growing prevalence of cardiovascular disease, the leading cause of death worldwide. Limitations of current stent products are fueling innovations by the three big heart players - Abbott, Boston Scientific and Medtronic - as well as startups to develop next-generation drug-eluting and bioresorbable stents that can reduce the risk of adverse event. This feature looks more closely at the competitive landscape of the overall vascular stent market focusing in particular on the changing dynamics of drug-eluting stents, which is the largest and second-fastest segment in this overall market, including its use for treating peripheral artery disease, along with physician surveys and perspectives.
You may also be interested in...
TCT 2018: Next-Gen Stents, Key Insights From Leading Experts
The Transcatheter Cardiovascular Therapeutics meeting held in San Diego featured late-breaking trials of new stent technologiesincluding TALENT, BIONYX, BIOFLOW-V, SORT-OUT IX, LEADERS FREE II and ReCre8.
Terumo Dives Into China DES Market With Essen Springboard
Terumo is adding China to its existing global drug-eluting stent (DES) sales network, with the agreed acquisition of Beijing-based Essen Technology. This is a modest acquisition for the Japanese group but could give it a springboard into a potentially lucrative and important DES market.
Starts & Stops: March 12-20, 2018
Starts & Stops features noteworthy clinical trial announcements, initiations, completions and suspensions tracked by Meddevicetracker. This edition covers the trial announcements between March 12-20, 2018, including clinical trial announcements from Boston Scientific, Biotronik, Johnson & Johnson and Edwards.